Status:
COMPLETED
The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males (MK-0000-127)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Hypertension
Eligibility:
MALE
18-60 years
Phase:
PHASE1
Brief Summary
This study will evaluate the effect of Aliskiren and Losartan on renal blood flow using PAH clearance, PC MRA and ASL MRI methodologies.
Eligibility Criteria
Inclusion
- Subject is in generally good health
- Subject is willing to avoid unaccustomed strenuous exercise during the study
- Subject agrees to consume ONLY the study-specified diet during all domiciled periods
- Subject has been a non-smoker for at least 3 months prior to study
- Subject will refrain from smoking or using any tobacco products during the study
- Subject agrees to refrain from consuming alcohol or caffeine during the domiciled periods and agrees to limit alcohol and caffeine consumption throughout the study
Exclusion
- Subject has contraindication to MRI scans
- Subject has a history of stroke, seizure, or major neurological disorders
- Subject uses illicit drugs or has a history of drug/alcohol abuse
- Subject has had major surgery, has donated or lost 1 unit of blood, or has been in another investigational study in the last 4 weeks
- Subject has a history of multiple and/or severe allergies to drugs or food
Key Trial Info
Start Date :
January 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00856960
Start Date
January 1 2010
End Date
April 1 2010
Last Update
January 22 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.